Denodo Adds to Executive Team with Key Appointments: Daniel Lender Joins as Chief Financial Officer and Stephen Welles as Chief Legal Officer
10.11.2022 11:00:00 EET | Business Wire | Press release
Denodo, a leader in data management, today announced two key additions to its executive team to help to guide Denodo through its next phase of growth: Daniel Lender as Chief Financial Officer and Stephen Welles as Chief Legal Officer. Mr. Lender and Mr. Welles will lead all of Denodo’s global financial and legal strategy and operations, reporting directly to Denodo’s Chief Executive Officer, Angel Viña.
“We’re excited to welcome Daniel as our new CFO and Stephen as our new CLO,” said Angel Viña, CEO and Founder of Denodo. “Daniel brings extensive financial and operational experience in enterprise software to our executive team and Stephen adds his broad and deep expertise in legal matters. These two key appointments strengthen our executive team and will be a great asset to Denodo as we continue to grow our global business.”
Daniel Lender is the newest addition to Denodo’s executive leadership team and brings more than 30 years of enterprise software and financial markets experience to his role. Mr. Lender joins Denodo after a long tenure with QAD Inc., a leading provider of next generation manufacturing and supply chain management solutions in the cloud, where he served as executive vice president and chief financial officer.
“I am absolutely thrilled to join Denodo at this stage,” said Daniel Lender. “With data growing at an exponential rate and multi-cloud platforms becoming the norm, I believe Denodo, with its unique and proprietary platform, is well positioned to continue its growth path and help its customers unlock value from their data. I look forward to working with the Denodo leadership team to help fuel Denodo’s next phase of growth.”
Stephen Welles brings more than 25 years of experience to his new position as Chief Legal Officer. He joined Denodo from Wilson Sonsini Goodrich & Rosati, the premier legal advisor to technology, life sciences, and other growth enterprises worldwide, where he was a senior counsel. Before that, he was the senior vice president and general counsel at Oplink Communications, an optical networking equipment company with more than 3,000 employees worldwide.
“Denodo has a bright future and I am excited to be a part of the team,” said Stephen Welles. “Denodo’s mission to help enterprises become data-driven organizations is an important one, and it will continue to drive Denodo’s growth.”
Denodo was recognized as a Leader in the 2022 Gartner® Magic Quadrant™ for Data Integration Tools for a third year in a row, and in the Forrester Wave™: Enterprise Data Fabric, Q2 2022 for a second year in a row. Denodo is the fastest growing vendor among the top 10 data integration vendors according to Gartner Market Share Analysis: Data Integration Software, Worldwide, 2021. Denodo also has been consistently receiving Customers’ Choice distinction in the Gartner Peer Insights 'Voice of the Customer': Data Integration Tools report for the last two years, showcasing how positively Denodo customers perceive the value of the product, services and support offered by Denodo.
Please tweet: News: @denodo adds to executive team - Daniel Lender as Chief Financial Officer and Stephen Welles as Chief Legal Officer to drive next phase of growth for #datamanagement and #dataintegration leader
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading data integration, management, and delivery platform using a logical approach to enable self-service BI, data science, hybrid/multi-cloud data integration, and enterprise data services. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across large enterprises and mid-market companies in 30+ industries have received payback in less than 6 months. For more information, visit www.denodo.com or call +1 877 556 2531 (US) / +44 (0) 20 7869 8053 (UK) / +65 6950 7489 (Singapore).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005616/en/
Contact information
Chris McCoin or Richard Smith
McCoin & Smith Communications Inc.
508-429-5988 (Chris) or 978-433-3304 (Rick)
chris@mccoinsmith.com or rick@mccoinsmith.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom